DOCSLIB.ORG

Transitional Cell Carcinoma: Options Beyond Nsaids Julie Marie Gillem, DVM, DACVIM (Oncology) Overview

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Transitional Cell Carcinoma: Options Beyond Nsaids Julie Marie Gillem, DVM, DACVIM (Oncology) Overview Transitional Cell Carcinoma: Options Beyond NSAIDs Julie Marie Gillem, DVM, DACVIM (Oncology) Overview ✦ Background ✦ Surgical Options ✦ Pathology ✦ Medical Options ✦ Location and staging ✦ Radiation Therapy ✦ Behavior Options ✦ Etiology and risk factors ✦ Palliative care ✦ Work up and diagnosis ✦ What about cats? Objectives ✦ How do we determine when NSAIDs fail? ✦ When should we intervene with surgery, chemotherapy, radiation therapy, and additional palliative care? Pathology ✦ ~2% of canine cancer ✦ Invasive transitional cell carcinoma (TCC) most common ✦ Others: SCC, adenocarcinoma, undifferentiated carcinoma, rhabdomyosarcoma, fibroma, and other mesenchymal tumors Location and Staging ✦ TCC in dogs most often found in the trigone of the bladder ✦ Series of 102 dogs at PUVTH ✦ Urethra and bladder in 56% ✦ Prostate involvement in 29% male dogs ✦ Lymph node mets in 16% at diagnosis ✦ Distant mets in 14% at diagnosis ✦ Distant mets in 50% at death Location ✦ TCC in dogs most often is found in the trigone region of the bladder. ✦ In a series of dogs with TCC examined at the PUVTH, the tumor involved the urethra as well as the bladder in 57 of 102 dogs (56%), and it involved the prostate in 11 of 38 (29%) male dogs. WHO Staging ✦ 78% T2 tumors ✦ 20% T3 tumors Biological Behavior ✦ At diagnosis: ✦ Regional lymph node metastasis in 12-46 % (Norris et al 1992, Knapp et al 2000, Blackburn et al 2013) ✦ Distant metastasis in 16- 23% (Norris et al 1992, Blackburn et al 2013) ✦ Distant metastasis in 50% at death (Norris et al 1992, Knapp et al 2000,) ✦ Locally aggressive! Etiology and Risk factors ✦ Identified risk factors : ✦ Exposure to topical insecticides and herbicides (Glickman et al 1989, Glickman et al 2004) ✦ Obesity (Glickman et al 1989) ✦ Possibly cyclophosphamide (Weller et al 1979, Macy et al 1983) ✦ Female gender (Knapp et al 2000, Mustaers et al 2003) ✦ Certain breeds (Knapp et al 2000) ✦ Vegetables may decrease risk (Raghavan et al 2005) Work Up and Diagnosis ✦ Initial Diagnostics ✦ Abdominal ultrasound ✦ Positive, or double contrast cystourethogram ✦ Chest radiographs Diagnosis ✦ Free Catch Cytospin (Knapp 2000) ✦ Traumatic catheterization±US guidance (Lamb 1996) ✦ Cystoscopy and surgical biopsy(Childress 2011) ✦ V-BTA test (Borjesson 1999) ✦ CADET BRAF Mutation detection assay (Mochizuki 2015) Diagnosis ✦ Caution with FNA Surgical Options ✦ Total cystectomy with re-routing of the urinary system ✦ Severe Complications ✦ 9/10 neurologic dysfunction ✦ 5/10 hyperchloremic metabolic acidosis ✦ 5/10 pyelonephritis ✦ Survival 1-5 months (MST not given) Kudnig and Seguin 2010 ✦ Not recommended due to the complications ✦ Attempted 1-2 cm margins ✦ 4/11 had microscopic dirty margins ✦ 9/11 dogs had tumor recurrence ✦ MST not evaluated ✦ En-bloc resection of trigone and proximal urethra discouraged due to major potential complications (incontinence, bladder necrosis) ✦ Technique involving complete resection of bladder neck, including trigone and proximal urethra, but preserving neurovascular pedicles to bladder and urethra ✦ Preserves LUT function and maintains continence ✦ ST for two dogs was 280 and 580 days ✦ Recurrence noted in both patients ✦ Continence achieved in both patients ✦ 37 dogs with partial cystectomy +/- additional therapies ✦ 60% had microscopic dirty margins ✦ 76% dogs had tumor recurrence ✦ Abdominal wall seeding in 11% ✦ PFI 235 d and MST 348 d ✦ MST for partial cystectomy + daily piroxicam +/- chemo- 772 d ✦ Non-trigonal location and frequency of piroxicam prognostic Cyto-reductive surgery ✦ Incomplete removal of a tumor (planned or unplanned) or debulking ✦ Removing 99.9% of 1-cm tumor (one billion cells) still leaves one million cancer cells ✦ Theoretical indication to enhance efficacy of other treatments ✦ Chemotherapy ✦ Radiation therapy ✦ Cryotherapy ✦ Few well-controlled clinical trials have shown benefit in vet med Surgical Debulking in TCC ✦ Surgical cure virtually impossible with “debulking” ✦ Various studies evaluate survival with surgery alone: ✦ Norris et al 1992: ✦ Survival dependent on perceived amount of tumor removed ✦ Determined location was important for prognosis ✦ 100% - MST 365 days ✦ 50-99% - MST 120 days ✦ <50% - MST 75 days ✦ Helfand et al 1994: ✦ MST - 86 days ✦ Data from the PCOP tumor registry: ✦ MST - 106 days Cyto-reductive Surgery with adjunctive therapy ✦ Norris et al 1992: ✦ MST for dogs with cytoreductive surgery and RT- 105 days ✦ MST for dogs with cytoreductive surgery and chemo- 30 days ✦ Knapp et al 2000: 102 dogs with TCC ✦ MST with surgical debulking plus medical therapy (piroxicam or chemotherapy) was 272 days ✦ MST for surgery for biopsy only plus medical therapy- 195 days ✦ MST for medical therapy alone- 150 days ✦ Josel et al 2002: 122 dogs with TCC ✦ MST with surgical debulking and chemo- 350 days ✦ MST with medical therapy alone- 207 days Cyto-reduction with a MIS approach ✦ Liptak et al 2004: Transurethral resection ✦ Not recommended in female dogs ✦ Upton et al 2006: CO2 laser ablation ✦ MST- 299 days ✦ Cerf et al 2012: Endoscopically utilized Diode laser ✦ MST 380 days Medical Options Medical Treatment ✦ COX inhibitors, chemotherapy, or combo ✦ Goal is palliation ✦ Can obtain remission or SD ✦ Therapy continued as long as TCC is controlled, SEs are acceptable, and QOL is good NSAIDs ✦ Inhibit cyclooxygenase (COX) ✦ Useful palliative treatment for dogs with TCC ✦ Watch for GI toxicities: vomiting, melena, anorexia ✦ COX-2 inhibitors (i.e. deracoxib) may be a little safer Uremicfrost.com Piroxicam ✦ 62 dogs at PUVTH w/ single agent piroxicam for TCC ✦ 18% ORR including 2 CRs via cystography ✦ MST 195 days ✦ 2 dogs with CR lived 2.1 and 3.3 years COX-2 Inhibitors • 17% ORR via ultrasonography w/ consistent degree of bladder distention • MST 323 days • 8 dogs had received prior tx with piroxicam and/ or chemotherapy How Do We Determine When NSAIDs Fail? ✦ Majority of treatment is palliative ✦ Response endpoints: ✦ Progression or development of clinical signs ✦ Objective increase in tumor measurements ✦ Urinary obstruction Tumor Measurements ✦ Traditional ultrasonography may not be most reliable measure of response Chemotherapy ✦ Many combos of single agent chemotherapy and NSAIDs used ✦ Mitoxantrone and piroxicam one of most common ✦ Benefit of multi-agent chemotherapy protocols not yet determined Zazzle.com Study Results re: Medical Therapy of Transitional Cell Carcinoma in Dogs Metastasis Drug Dogs (#) (%) ORR (%) CR (%) PR (%) SD (%) PD (%) PFI (days) MST (days) Single Arm Trials Piroxicam 34 23 18 6 12 53 29 NA 181 Deracoxib 26/24 15 17 0 17 71 12 133 323 Mitoxantrone/ piroxicam 55/48 11 35 2 33 46 19 (194) 160 (350) 291 Vinblastine 28 28 36 0 36 50 14 122 147 Cisplatin (40-50 mg/m2)/ piroxicam 14 7 7 0 7 36 57 78 307 Carboplatin 14/12 28 0 0 0 8 92 41 132 Carboplatin/ piroxicam 31/29 19 38 0 38 45 17 NA 161 Intravesical Mitomycin C 13/12 0 42 0 42 58 0 120 223 Gemcitabine/ piroxicam 38/37 11 27 5 22 51 22 NA 230 Metronomic chlorambucil 31/30 32 3 0 3 67 30 119 221 Vinblastine (1.6 mg/m2)/ tocerinib (2.5-2.75 mg/kg) 5/10 20 40 0 40 60 0 NA NA Randomized Trials Cisplatin (60 mg/m2) 8 12 0 0 0 50 50 84 300 Cisplatin (60 mg/m2)/ piroxicam 14 43 14 14 57 28 0 124 246 Cisplatin (60 mg/m2) 15 33 13 0 13 53 27 87 338 Firocoxib 15 53 20 0 20 33 27 105 152 Cisplatin (60 mg/m2)/ firocoxib 14 29 57 0 57 21 0 186 179 Mitoxantrone/ piroxicam 26 8 8 0 8 69 23 106 248 Carboplatin/ piroxicam 24 41 13 0 13 54 33 74 263 Vinblastine (2.5 mg/m2) 27 11 58 0 58 33 8 143 407 Vinblastine (2.5 mg/m2)/ piroxicam 24 4 22 0 22 70 4 199 299 Retrospective Studies Doxorubicin/ piroxicam 34/23 29 9 0 9 60.5 30.5 103 168 Vinorelbine 14/12 0 14 0 14 57 14 93 187 Cisplatin (60 mg/m2) 18/16 33 19 0 19 25 56 75 130 Cistplatin (50 mg/m2) 15/12 40 25 0 25 50 25 NA 105 ✦ Nonrandomized one armed prospective clinical trial with 55 dogs ✦ 34.5% ORR via cystosonography ✦ Subjective improvement in 75% via owner observation ✦ PFI 194/ 160 days ✦ MST 350/ 291 days ✦ 9% ORR via cystosonography ✦ 1 dog had subjective response based on CSs and QOL, but no imaging ✦ PFI 103 days ✦ MST 168 days ✦ Well tolerated but modest response rates ✦ OS significantly improved in patients who underwent cytoreductive sx Platinums ✦ Cisplatin ✦ Higher reported remission rates (50-70%), but limited by renal damage ✦ ORR 57% with combination via cystography (13% for cisplatin alone and 20% for firocoxib alone) ✦ Renal and GI toxicosis common ✦ Carboplatin ✦ 38% ORR via cystography and cystosonography ✦ MST 161 days ✦ GI and hematologic toxicities; no renal toxicity ✦ No response difference between groups ✦ Mitoxantrone group (26): 8% PR and 69% SD ✦ Carboplatin group (24): 13% PR and 54% SD ✦ 106 d PFI for mitoxantrone versus 73.5 d PFI for carboplatin- not sign ✦ Prostatic involvement- shorter MST- 109 d vs 300 d (urethral), 190 d (trigonal), and 645 d (apical) ✦ 38 dogs evaluated ✦ 27% ORR via ultrasonography w/ consistent bladder distension and single ultrasonographer ✦ MST 230 days ✦ Limited adverse effects ✦ Prospective clinical trial of 28 dogs ✦ 18 dogs had tx prior to trial ✦ 36% ORR via ultrasonography w/ single ultrasonographer ✦ MST 147 days ✦ Maj. (27/28) did not have clinically relevant adverse effects ✦ Prospective and retrospective clinical trial with 14 dogs (13 relapsed, 1 naïve) ✦ 14% ORR via ultrasonography ✦ Subjective improvement in CSs in 11/14 ✦ Mild adverse effects ✦ PFI 93 days ✦ MST 187 days ✦ Dogs receiving dose reduction had MST of 130 d vs 222 d ✦ 8 dogs received additional tx after, but no
Load more

Recommended publications
  • MASCC/ESMO ANTIEMETIC GUIDELINE 2016 with Updates in 2019
    1 ANTIEMETIC GUIDELINES: MASCC/ESMO MASCC/ESMO ANTIEMETIC GUIDELINE 2016 With Updates in 2019 Organizing and Overall Meeting Chairs: Matti Aapro, MD Richard J. Gralla, MD Jørn Herrstedt, MD, DMSci Alex Molassiotis, RN, PhD Fausto Roila, MD © Multinational Association of Supportive Care in CancerTM All rights reserved worldwide. 2 ANTIEMETIC GUIDELINES: MASCC/ESMO These slides are provided to all by the Multinational Association of Supportive Care in Cancer and can be used freely, provided no changes are made and the MASCC and ESMO logos, as well as date of the information are retained. For questions please contact: Matti Aapro at [email protected] Chair, MASCC Antiemetic Study Group or Alex Molassiotis at [email protected] Past Chair, MASCC Antiemetic Study Group 3 ANTIEMETIC GUIDELINES: MASCC/ESMO Consensus A few comments on this guideline set: • This set of guideline slides represents the latest edition of the guideline process. • This set of slides has been endorsed by the MASCC Antiemetic Guideline Committee and ESMO Guideline Committee. • The guidelines are based on the votes of the panel at the Copenhagen Consensus Conference on Antiemetic Therapy, June 2015. • Latest version: March 2016, with updates in 2019. 4 ANTIEMETIC GUIDELINES: MASCC/ESMO Changes: The Steering Committee has clarified some points: 2016: • A footnote clarified that aprepitant 165 mg is approved by regulatory authorities in some parts of the world ( although no randomised clinical trial has investigated this dose ). Thus use of aprepitant 80 mg in the delayed phase is only for those cases where aprepitant 125 mg is used on day 1. • A probable modification in pediatric guidelines based on the recent Cochrane meta-analysis is indicated.
    [Show full text]
  • Modifications on the Basic Skeletons of Vinblastine and Vincristine
    Molecules 2012, 17, 5893-5914; doi:10.3390/molecules17055893 OPEN ACCESS molecules ISSN 1420-3049 www.mdpi.com/journal/molecules Review Modifications on the Basic Skeletons of Vinblastine and Vincristine Péter Keglevich, László Hazai, György Kalaus and Csaba Szántay * Department of Organic Chemistry and Technology, University of Technology and Economics, H-1111 Budapest, Szt. Gellért tér 4, Hungary * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel: +36-1-463-1195; Fax: +36-1-463-3297. Received: 30 March 2012; in revised form: 9 May 2012 / Accepted: 10 May 2012 / Published: 18 May 2012 Abstract: The synthetic investigation of biologically active natural compounds serves two main purposes: (i) the total synthesis of alkaloids and their analogues; (ii) modification of the structures for producing more selective, more effective, or less toxic derivatives. In the chemistry of dimeric Vinca alkaloids enormous efforts have been directed towards synthesizing new derivatives of the antitumor agents vinblastine and vincristine so as to obtain novel compounds with improved therapeutic properties. Keywords: antitumor therapy; vinblastine; vincristine; derivatives 1. Introduction Vinblastine (1) and vincristine (2) are dimeric alkaloids (Figure 1) isolated from the Madagaskar periwinkle plant (Catharantus roseus), exhibit significant cytotoxic activity and are used in the antitumor therapy as antineoplastic agents. In the course of cell proliferation they act as inhibitors during the metaphase of the cell cycle and by binding to the microtubules inhibit the development of the mitotic spindle. In tumor cells these agents inhibit the DNA repair and the RNA synthesis mechanisms, blocking the DNA-dependent RNA polymerase. Molecules 2012, 17 5894 Figure 1.
    [Show full text]
  • National Dose Banding Table – Single Container
    National Dose Banding Table – Single Container Arsenic Trioxide Cisplatin Cladribine (Leustat) Strength of raw material 1 mg/mL Example drug(s) Idarubicin (after reconstitution if required) Mitomycin Vinblastine Vincristine See table usage notes below regarding ‘single container’ and ‘multiple syringe’ tables. Master Bands and Ranges This table is intended to be in a format useful for electronic prescribing systems. Use To (A) if your system will round UP for doses on the step between two bands. Use To (B) if your system will round DOWN for doses on the step between two bands. Band Range (mg) Band Dose Variance (percent) From ≥ To (A) < To (B) ≤ (mg) Below Above 0.21 0.23 0.22 0.22 5 -4 0.23 0.25 0.24 0.24 4 -4 0.25 0.27 0.26 0.26 4 -4 0.27 0.29 0.28 0.28 4 -3 0.29 0.32 0.31 0.3 3 -6 0.32 0.36 0.35 0.34 7 -5 0.36 0.40 0.39 0.38 6 -5 0.40 0.44 0.43 0.42 5 -5 0.44 0.49 0.48 0.46 5 -6 0.49 0.55 0.54 0.52 6 -5 0.55 0.61 0.60 0.58 6 -5 0.61 0.68 0.67 0.64 5 -6 0.68 0.76 0.75 0.72 6 -5 0.76 0.85 0.84 0.8 5 -6 0.85 0.95 0.94 0.9 6 -5 0.95 1.05 1.04 1 5 -5 1.05 1.15 1.14 1.1 5 -4 1.15 1.25 1.24 1.2 4 -4 1.25 1.35 1.34 1.3 4 -4 1.35 1.45 1.44 1.4 4 -3 1.45 1.55 1.54 1.5 4 -3 1.55 1.65 1.64 1.6 3 -3 1.65 1.75 1.74 1.7 3 -3 1.75 1.90 1.89 1.8 3 -5 1.90 2.10 2.09 2 5 -5 2.10 2.30 2.29 2.2 5 -4 2.30 2.50 2.49 2.4 4 -4 2.50 2.70 2.69 2.6 4 -4 2.70 2.90 2.89 2.8 4 -3 2.90 3.10 3.09 3 4 -3 3.10 3.30 3.29 3.2 3 -3 3.30 3.50 3.49 3.4 3 -3 3.50 3.80 3.79 3.6 3 -5 3.80 4.20 4.19 4 5 -5 4.20 4.60 4.59 4.4 5 -4 Chemotherapy Dose Standardisation Band Range (mg)
    [Show full text]
  • Combining Paclitaxel and Lapatinib As Second-Line Treatment for Patients with Metastatic Transitional Cell Carcinoma: a Case Series
    ANTICANCER RESEARCH 32: 3949-3952 (2012) Combining Paclitaxel and Lapatinib as Second-line Treatment for Patients with Metastatic Transitional Cell Carcinoma: A Case Series STÉPHANE CULINE, ZINEB SELLAM, LINDA BOUAITA, ELIAS ASSAF, CATHERINE DELBALDO, MURIEL VERLINDE-CARVALHO and DAMIEN POUESSEL Department of Medical Oncology, Henri Mondor Hospital, Créteil, France Abstract. Background: Current first-line cisplatin-based trial comparing vinflunine with best supportive care (BSC) combination chemotherapy regimens provide interesting to BSC alone, an estimated difference in overall survival response rates but limited impact on survival for patients with (OS) of 2 months was reached in the intent-to-treat metastatic transitional cell carcinoma of the urothelium. Such population. However, a significant difference in OS was only results leave a significant patient population in need of salvage seen after removing patients who had major protocol therapy. Patients and Methods: As the epidermal growth factor violations (2). Therefore therapy for patients who fail first- receptors 1 and 2 (EGFR and HER2) are frequently line cisplatin-based chemotherapy remains a highly unmet overexpressed in urothelial carcinoma, we explored the medical need. feasibility of a combination of paclitaxel (80 mg/m2/week) and In a phase II study led by the French Genito-Urinary lapatinib (1,500 mg orally daily) for six patients who were Tumor group (GETUG), the activity of weekly paclitaxel as treated after failure of first-line platinum-based chemotherapy. second-line chemotherapy was assessed in 45 patients with Results: Only one out of six patients was able to receive the MTCCU. A low objective response rate (9%) along with a full doses during the first six weeks of treatment, while grade high rate of stabilization (38%) suggested limited impact as 2 or 3 diarrhea events required lapatinib dose reduction (one a single agent (3).
    [Show full text]
  • Hodgkin Lymphoma Treatment Regimens
    HODGKIN LYMPHOMA TREATMENT REGIMENS (Part 1 of 5) Clinical Trials: The National Comprehensive Cancer Network recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced health care team. Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive care interventions should be administered accordingly. The cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/regimens. These regimens are provided only to supplement the latest treatment strategies. These Guidelines are a work in progress that may be refined as often as new significant data become available. The NCCN Guidelines® are a consensus statement of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. Classical Hodgkin Lymphoma1 Note: All recommendations are Category 2A unless otherwise indicated. Primary Treatment Stage IA, IIA Favorable (No Bulky Disease, <3 Sites of Disease, ESR <50, and No E-lesions) REGIMEN DOSING Doxorubicin + Bleomycin + Days 1 and 15: Doxorubicin 25mg/m2 IV push + bleomycin 10units/m2 IV push + Vinblastine + Dacarbazine vinblastine 6mg/m2 IV over 5–10 minutes + dacarbazine 375mg/m2 IV over (ABVD) (Category 1)2-5 60 minutes.
    [Show full text]
  • Non-Steroidal Anti-Inflammatory Drugs Inhibit Bone Healing: a Review S
    Review Article © Schattauer 2010 385 Non-steroidal anti-inflammatory drugs inhibit bone healing: A review S. Barry Washington State University, Department of Veterinary Clinical Sciences, Veterinary Teaching Hospital, Pullman, Wash- ington, USA crine and autocrine activity, have since Keywords stems from prostaglandin inhibition and is been shown to regulate constitutive and in- Non-steroidal anti-inflammatory drugs, likely multifactorial. In human medicine ducible functions throughout the body, in- NSAID, bone healing NSAID are known to prevent heterotopic ossi- cluding bone healing (5–9). The mech- fication, however the clinical importance of anism of NSAID inhibition to bone healing Summary their effects on bone healing remains contro- is unknown, but is likely multifactorial. Re- The ability of non-steroidal anti-inflammatory versial. Although a small handful of reports searchers have suggested that NSAID affect drugs (NSAID) to inhibit bone healing has suggest that NSAID suppress bone healing in normal bone healing in multiple ways, with been established in experimental animal dogs and horses, there is little published infor- emphasis often (but not exclusively) placed models using mice, rats, and rabbits. The mation to direct veterinary practice in do- on processes related to the inflammatory mechanism of action is largely unknown but mestic species. stage. Deciphering the mechanism of NSAID inhibition requires an understanding of Correspondence to: Vet Comp Orthop Traumatol 2010; 23: 385–392 Sabrina Barry, DVM doi:10.3415/VCOT-10-01-0017 fracture healing. Fracture healing presents Washington State University Received: January 31, 2010 an exquisitely orchestrated series of coor- Department of Veterinary Clinical Sciences Accepted: June 23, 2010 dinated molecular and cellular events.
    [Show full text]
  • Latest Administration Hour Prior to Competition Max Dosage Per Pound of Body Weight Medication Trade Name Medication Generic Name
    MEDICATION MEDICATION MAX DOSAGE PER POUND LATEST ADMINISTRATION HOUR ADMINISTRATION METHOD GENERIC NAME TRADE NAME OF BODY WEIGHT PRIOR TO COMPETITION (single dose per 24 hours unless specified otherwise) Dexamethasone Azium® 2.0 mg/100Lb >12 hours IV, IM (20 mg/1000Lb) or 0.5 mg/100Lb >6 hours IV (5.0 mg/1000Lb) or 1.0 mg/100LB >6 hours Oral (10 mg/1000Lb) Diclofenac Surpass® 5 inch ribbon, 1⁄2 inch thick, >12 hours Topical, 2 doses each day 12 hours apart one site Firocoxib Equioxx® 0.1 mg/kg >12 hours Oral (0.0455 mg/Lb) (45.5 mg/1000Lb) Phenylbutazone (“bute”) * Butazolidin® 2.0 mg/Lb >12 hours Oral, IV (2.0 grams/1000Lb) or 1.0 mg/Lb AM & PM feed Oral, 2 doses each day, 12 hours apart (1.0 grams/1000Lb) Flunixin meglumine * Banamine® 0.5 mg/Lb >12 hours Oral, IV (500 mg/1000Lb) Ketoprofen Ketofen® 1.0 mg/Lb >4 hours, but IV (1.0 gram/1000Lb) >6 hours is recommended Meclofenamic acid Arquel® 0.5 mg/Lb Oral, 2 doses each day, 12 hours apart (500 mg/1000Lb) Naproxen Naprosyn® 4.0 mg/Lb >12 hours Oral (4.0 grams/1000Lb) Eltenac Not yet approved Telzenac® 0.25 mg/Lb (250 mg/1000Lb) 12 hours IV Methocarbamol Robaxin® 5.0 mg/Lb >6 hours Oral, IV, 2 doses each day, 12 hours apart (5.0 grams/1000Lb) * Do not administer phenylbutazone and flunixin at the same time (Unless used according to The maximum treatment time for any of the above permitted medication is five days, with the Section 8).
    [Show full text]
  • Simultaneous Determination of Residues of Non-Steroidal Anti-Inflammatory Drugs and Glucocorticosteroids in Animal Muscle By
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Springer - Publisher Connector Food Anal. Methods (2016) 9:1837–1848 DOI 10.1007/s12161-015-0352-y Simultaneous Determination of Residues of Non-Steroidal Anti-Inflammatory Drugs and Glucocorticosteroids in Animal Muscle by Liquid Chromatography-Tandem Mass Spectrometry Piotr Jedziniak1 & Małgorzata Olejnik1 & Konrad Pietruk1 & Edyta Protasiuk1 & Teresa Szprengier-Juszkiewicz1 & Jan Żmudzki1 Received: 11 February 2015 /Accepted: 4 November 2015 /Published online: 21 November 2015 # The Author(s) 2015. This article is published with open access at Springerlink.com Abstract A method for the determination of a wide range Introduction residues of anti-inflammatory drugs (16 acidic non-steroidal anti-inflammatory drugs and four metamizole metabolites and Non-steroidal anti-inflammatory drugs (NSAIDs) and five corticosteroids) has been was developed. In the first step glucocorticosteroids (GCs) are widely used in veterinary medi- of sample preparation, acetate buffer was added to minced cine as well as in treatment of diseases in food-producing ani- muscle samples and 15-min ultrasound-assisted enzymatic mals. Despite its effectiveness, the important drawback of phar- hydrolysis was performed. Next, the samples were extracted macotherapy is drug residues in animal tissues. It became an twice with acetonitrile, freezed and analysed. The analytes important issue in the food safety. Potential toxicity of medicinal were separated on a C18 column with a 25-min gradient of veterinary products has to be evaluated before the drug registra- methanol/acetonitrile (8:2) and 0.05 M ammonium formate at tion. When necessary, maximum residue limits (MRLs) in food pH 5.0 and determined by liquid chromatography-tandem are established.
    [Show full text]
  • Non-Steroidal Anti-Inflammatory Drugs As Chemopreventive Agents: Evidence from Cancer Treatment in Domestic Animals
    Annual Research & Review in Biology 26(1): 1-13, 2018; Article no.ARRB.40829 ISSN: 2347-565X, NLM ID: 101632869 Non-Steroidal Anti-Inflammatory Drugs as Chemopreventive Agents: Evidence from Cancer Treatment in Domestic Animals Bianca F. Bishop1 and Suong N. T. Ngo1* 1School of Animal and Veterinary Sciences, The University of Adelaide, Roseworthy, SA 5371, Australia. Authors’ contributions This work was carried out in collaboration between both authors. Author BFB performed the collection and analysis of the data. Author SNTN designed the study, managed the analyses and interpretation of the data and prepared the manuscript. Both authors read and approved the final manuscript. Article Information DOI: 10.9734/ARRB/2018/40829 Editor(s): (1) David E. Martin, Martin Pharma Consulting, LLC, Shawnee, OK, USA. (2) George Perry, Dean and Professor of Biology, University of Texas at San Antonio, USA. Reviewers: (1) Fulya Ustun Alkan, Istanbul University, Turkey. (2) Thompson Akinbolaji, USA. (3) Ramesh Gurunathan, Sunway Medical Center, Malaysia. (4) Mohamed Ahmed Mohamed Nagy Mohamed, El Minia Hospital, Egypt. Complete Peer review History: http://www.sciencedomain.org/review-history/24385 Received 10th February 2018 Accepted 21st April 2018 Review Article Published 30th April 2018 ABSTRACT Aims: This study aims to systematically review currently available data on the use of non-steroidal anti-inflammatory drugs (NSAIDs) in the treatment of cancer in domestic animals to evaluate the efficacy of different treatment protocols and to suggest further recommendations for future study. Methodology: Literature data on the use of NSAIDs in domestic animals as chemo-preventive agents in the last decade were collected and critically reviewed.
    [Show full text]
  • BC Cancer Benefit Drug List September 2021
    Page 1 of 65 BC Cancer Benefit Drug List September 2021 DEFINITIONS Class I Reimbursed for active cancer or approved treatment or approved indication only. Reimbursed for approved indications only. Completion of the BC Cancer Compassionate Access Program Application (formerly Undesignated Indication Form) is necessary to Restricted Funding (R) provide the appropriate clinical information for each patient. NOTES 1. BC Cancer will reimburse, to the Communities Oncology Network hospital pharmacy, the actual acquisition cost of a Benefit Drug, up to the maximum price as determined by BC Cancer, based on the current brand and contract price. Please contact the OSCAR Hotline at 1-888-355-0355 if more information is required. 2. Not Otherwise Specified (NOS) code only applicable to Class I drugs where indicated. 3. Intrahepatic use of chemotherapy drugs is not reimbursable unless specified. 4. For queries regarding other indications not specified, please contact the BC Cancer Compassionate Access Program Office at 604.877.6000 x 6277 or [email protected] DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES Therapy for Metastatic Castration-Sensitive Prostate Cancer using abiraterone tablet Genitourinary UGUMCSPABI* R Abiraterone and Prednisone Palliative Therapy for Metastatic Castration Resistant Prostate Cancer abiraterone tablet Genitourinary UGUPABI R Using Abiraterone and prednisone acitretin capsule Lymphoma reversal of early dysplastic and neoplastic stem changes LYNOS I first-line treatment of epidermal
    [Show full text]
  • Oxaliplatin, 5-Fluorouracil and Leucovorin (FOLFOX) As Second- Line Therapy for Patients with Advanced Urothelial Cancer
    www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 36 Clinical Research Paper Oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) as second- line therapy for patients with advanced urothelial cancer Sheng Zhang1, Hongxi Xue2, Qiang Chen3 1Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China 2Rizhao City Hospital of Traditional Chinese Medicine, Rizhao, China 3Department of Clinical Biochemistry, School of Public Health, Taishan Medical University, Tai’an, China Correspondence to: Sheng Zhang, email: [email protected] Keywords: urothelial cancer, oxaliplatin, leucovorin, 5-fluorouracil, clinical trial Received: February 08, 2016 Accepted: June 30, 2016 Published: July 07, 2016 ABSTRACT There is currently no standard treatment for metastatic urothelial cancer after failure of cisplatin-based therapy. The present retrospective study investigated the efficacy and safety of oxaliplatin plus 5-fluorouracil (5-FU) and leucovorin (LV) (FOLFOX) in locally advanced or metastatic urothelial cancer patients following cisplatin-based treatment. Thirty-three patients who had received one or two cisplatin-based regimens were treated with oxaliplatin (85 mg/m2) as a 2-h infusion on day 1, LV (200 mg/m2) as a 2-h infusion followed by bolus 5-FU (400 mg/m2) on day 1, or a 44-h continuous 5-FU (1,200 mg/m2) infusion. Patients were a mean of 67 years old with two involved organs. Metastases were mostly in the lung (43%), lymph nodes (51%) and liver (46%). Based on an intention-to-treat analysis, nine patients achieved a partial response, with an overall response rate of 27%. Eight (24%) patients had stable disease.
    [Show full text]
  • Eliminating Vincristine Administration Events
    Issue 37 October 2017 Eliminating vincristine administration events Issue: Despite the usually deadly consequences of accidentally administering the chemotherapy drug vincristine intrathecally, adverse events still occur, typically because some organizations still administer vincristine via syringe. The good news is that these events are happening less in the United States, mostly because of the efforts of leading national organizations to promote an effective prevention strategy that assures a mechanical barrier to intrathecal administration (into the subarachnoid space). The strategy involves diluting intravenous vincristine or other vinca alkaloids in a minibag that contains a volume that is too large for intrathecal administration (e.g., 25 mL for pediatric patients and 50 mL for adults), making it mechanically difficult to accidentally administer intrathecally.1 Vinca alkaloids (vinblastine, vinorelbine, vincristine, and vincristine liposomal) are chemotherapy drugs that are intended to be administered intravenously. If given intrathecally, vincristine is nearly always fatal and associated with an irreversible, painful ascending paralysis.2 When vinca alkaloids are injected intrathecally, destruction of the central nervous system occurs, radiating out from the injection site. The few survivors of this adverse event experienced devastating neurological damage.1 Part of the problem stems from ordering intravenous vincristine in conjunction with medications that are administered intrathecally via a syringe, such as methotrexate, cytarabine and hydrocortisone. In some adverse events, vincristine was mistakenly injected into the cerebrospinal fluid (CSF) of patients when the intent was to inject another intrathecal chemotherapy agent, such as methotrexate or cytarabine.3 Intravenous vincristine and other vinca alkaloids are dispensed from the pharmacy with explicit warning labels about their lethality if given intrathecally.
    [Show full text]